TABLE 1
FROM:
Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults
H Narimatsu, S Terakura, K Matsuo, T Oba, T Uchida, H Iida, M Hamaguchi, M Watanabe, A Kohno, M Murata, M Sawa, K Miyamura and Y Morishita for the Nagoya Blood and Marrow Transplantation Group (NBMTG)
BACK TO ARTICLETable 1. CBT patient characteristics
| Variables | Number |
|---|---|
| Age (years) | |
| |[emsp]|Median, range | 48 (18|[ndash]|69) |
| Sex | |
| |[emsp]|Male|[sol]|female | 31|[sol]|46 |
| Primary disease | |
| |[emsp]|Acute myeloid leukemia | 30 |
| |[emsp]|Malignant lymphoma | 11 |
| |[emsp]|Acute lymphoblastic leukemia | 8 |
| |[emsp]|Chronic myelogenous leukemia | 7 |
| |[emsp]|Adult T-cell leukemia | 7 |
| |[emsp]|Myelodysplastic syndrome | 6 |
| |[emsp]|Aplastic anemia | 3 |
| |[emsp]|Multiple myeloma | 3 |
| |[emsp]|Chronic lymphocytic leukemia | 1 |
| |[emsp]|Chronic active EB-virus infection | 1 |
| Risk of underlying disease | |
| |[emsp]|High|[sol]|low | 51|[sol]|26 |
| Blood-type mismatch (match|[sol]|mismatch) | 21|[sol]|56 |
| Previous transplant | |
| |[emsp]|Autologous|[sol]|allogeneic | 8|[sol]|6 |
| Preparative regimen | |
| |[emsp]|Myeloablative regimen | |
| |[emsp]||[emsp]|CY 120|[thinsp]|mg|[sol]|m2|[plus]|TBI 8|[ndash]|12|[thinsp]|Gy | 9 |
| |[emsp]||[emsp]|BU 8|[thinsp]|mg|[sol]|kg|[plus]|L-PAM 120|[ndash]|180|[thinsp]|mg|[sol]|m2|[plus]|TBI 10|[thinsp]|Gy | 7 |
| |[emsp]||[emsp]|L-PAM 180|[thinsp]|mg|[sol]|m2|[plus]|TBI 8|[ndash]|10|[thinsp]|Gy | 6 |
| |[emsp]||[emsp]|BU 8|[ndash]|16|[thinsp]|mg|[sol]|kg|[plus]|CY 120|[thinsp]|mg|[sol]|kg|[plus]|TBI 7.5|[ndash]|10|[thinsp]|Gy | 5 |
| |[emsp]||[emsp]|BU 16|[thinsp]|mg|[sol]|kg|[plus]|CY 120|[thinsp]|mg|[sol]|kg | 3 |
| |[emsp]||[emsp]|CA 2|[thinsp]|g|[sol]|m2|[plus]|CY 120|[thinsp]|mg|[sol]|kg|[plus]|TBI 12|[thinsp]|Gy | 1 |
| |[emsp]|Reduced-intensity regimen | |
| |[emsp]||[emsp]|Flud 125|[ndash]|150|[thinsp]|mg|[sol]|m2|[plus]|L-PAM 80|[ndash]|140|[thinsp]|mg|[sol]|m2|[plus]|TBI 2|[ndash]|4|[thinsp]|Gy | 15 |
| |[emsp]||[emsp]|Flud 125|[thinsp]|mg|[sol]|m2|[plus]|L-PAM 60|[ndash]|180|[thinsp]|mg|[sol]|m2|[plus]|BU 4|[ndash]|8|[thinsp]|mg|[sol]|kg | 11 |
| |[emsp]||[emsp]|Flud 125|[thinsp]|mg|[sol]|m2|[plus]|L-PAM 140|[ndash]|180|[thinsp]|mg|[sol]|m2 | 8 |
| |[emsp]||[emsp]|Flud 125|[ndash]|150|[thinsp]|mg|[sol]|m2|[plus]|CY 25|[ndash]|60|[thinsp]|mg|[sol]|kg|[plus]|TBI 2|[ndash]|4|[thinsp]|Gy | 6 |
| |[emsp]||[emsp]|Flud 180|[thinsp]|mg|[sol]|kg|[plus]|BU 8|[thinsp]|mg|[sol]|kg | 3 |
| |[emsp]||[emsp]|Flud 125|[thinsp]|mg|[sol]|m2|[plus]|CY 30|[thinsp]|mg|[sol]|kg | 1 |
| |[emsp]||[emsp]|Flud 180|[thinsp]|mg|[sol]|m2|[plus]|thio-tepa 10|[thinsp]|mg|[sol]|kg|[plus]|ATG 5|[thinsp]|mg|[sol]|kg | 1 |
| |[emsp]||[emsp]|Flud 125|[thinsp]|mg|[sol]|m2|[plus]|VP-16 1800|[thinsp]|mg|[sol]|m2|[plus]|L-PAM 140|[thinsp]|mg|[sol]|m2|[plus]|CY 120|[thinsp]|mg|[sol]|kg | 1 |
| Number of infused nuclear cells | |
| |[emsp]|Median (range), 107|[sol]|kg | 2.50 (1.07|[ndash]|3.89) |
| Number of infused CD34|[plus]| cells | |
| |[emsp]|Median (range), 106|[sol]|kg | 0.11 (0.02|[ndash]|1.36) |
| HLA matching | |
| |[emsp]|6|[sol]|6 | 8 |
| |[emsp]|5|[sol]|6 | 37 |
| |[emsp]|4|[sol]|6 | 32 |
| GVHD prophylaxis | |
| |[emsp]|Cyclosporine alone | 23 |
| |[emsp]|Tacrolimus alone | 12 |
| |[emsp]|Cyclosporine|[plus]|short-term MTX | 17a |
| |[emsp]|Tacrolimus|[plus]|short-term MTX | 23b |
| |[emsp]|Tacrolimus|[plus]|mPSL 1|[thinsp]|mg|[sol]|kg | 2 |
Abbreviations: ATG|[equals]|antithymocyte globulin; BU|[equals]|busulfan; CA|[equals]|cytarabine; CY|[equals]|cyclophosphamide; EB|[equals]|Epstein|[ndash]|Barr; Flud|[equals]|fludarabine; GVHD|[equals]|graft-versus-host disease; HLA|[equals]|human leukocyte antigen; L-PAM|[equals]|melphalan; mPSL|[equals]|methylprednisolone; MTX|[equals]|methotrexate; TBI|[equals]|total body irradiation; VP-16|[equals]|etoposide.
Acute leukemia in complete remission, chronic myelogenous leukemia in chronic phase, malignant lymphoma in complete remission, multiple myeloma in complete remission, myelodysplastic syndrome in refractory anemia (RA), and aplastic anemia were defined as low risk. All other conditions were defined as high risk.
a Patients received 10, 7 and 7|[thinsp]|mg|[sol]|m2 of MTX on days 1, 3 and 6, respectively.
b MTX was given at doses of 15, 10 and 10|[thinsp]|mg|[sol]|m2 on days 1, 3 and 6 (n|[equals]|7), at doses of 10, 7 and 7|[thinsp]|mg|[sol]|m2 on days 1, 3 and 7 (n|[equals]|15) and at doses of 6 and 4|[thinsp]|mg|[sol]|m2 on days 1 and 3 (n|[equals]|1), respectively.
